Skip to Main Content

Paper Details

A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Int J Gynecol Cancer
2
2023
Author NameAffiliation
Shekhar GhamandeAugusta University Medical College of Georgia
  • 1 - 1

Datasets

Release 1.2